Healthcare, Pharma, Medical Device etc.
Category
Japan, United states of America, Europe, Rest of World
Geographic Coverage
Not Available
Video URL
Not Available
Sale price (USD)
Not Available
Non-exclusive license price (USD)
Not Available
Exclusive license price (USD)
Not Available
Non-exclusive license royalty rate %
Availability
Patent family
Number of members in the patent family
Assignee(s) / Patent owner(s)
To see the additional information details please login and subscribe to a Premium account.

Apolipoprotein E type 4

Patent Granted The E4 variant is the largest known genetic risk factor for late-onset sporadic Alzheimer disease (AD) in a variety of ethnic groups.[35] Caucasian and Japanese carriers of 2 E4 alleles have between 10 and 30 times the risk of developing AD by 75 years of age, as compared to those not carrying any E4 alleles. While the exact mechanism of how E4 causes such dramatic effects remains to be fully determined, evidence has been presented suggesting an interaction with amyloid.[36] Alzheimer disease is characterized by build-ups of aggregates of the peptide beta-amyloid. Apolipoprotein E enhances proteolytic break-down of this peptide, both within and between cells. The isoform ApoE-ε4 is not as effective as the others at catalyzing these reactions, resulting in increased vulnerability to AD in individuals with that gene variation.

GET LICENSE BROKER APPLY submit an inquiry
photo To see the additional information details please login and subscribe to a Plus or Premium account.